Oxford Cannabinoid Technologies Holdings Ltd's co-founder and executive chairman Neil Mahapatra talks to Proactive London ahead of their London initial public offer on Friday 21st May.
The firm have raised £16.5mln to develop cannabis-based pain treatments and are expected to reach a valuation on listing of around £51mln.
With the company focussed on medicines that mimic the painkilling effects of cannabis, it plans to use the funds raised in the IPO to help develop a portfolio of four drug candidates for approval as licensed pain medicines, with the aim of commercializing the company's first drug in 2027.